William Newhard

Merck & Co., Inc., Rahway, NJ, USA (United States)

Papers

2

Total Citations

12

H-Index

2

About

William Newhard is a researcher at the forefront of infectious disease pharmacology, with a primary focus on HIV latency reversal and antibacterial pharmacodynamics. His work addresses two critical challenges: eradicating persistent HIV reservoirs and streamlining the evaluation of antibiotic efficacy. Newhard’s major contributions include the development of an automated platform for *in vitro* pharmacokinetic/pharmacodynamic (PK/PD) modeling of HIV latency reversal, specifically testing novel histone deacetylase inhibitors (HDACis). This work, cited 6 times, provides a high-throughput method to identify compounds that can “shock and kill” latent HIV, a key barrier to a cure. Additionally, he pioneered a fully automated agar-based system for measuring viable bacterial growth, also with 6 citations, which significantly reduces manual labor in dynamic antibacterial studies. This innovation enables more efficient dosing strategy assessments before moving to *in vivo* models. By integrating automation into complex PK/PD analyses, Newhard is accelerating the discovery of effective therapies for both HIV and bacterial infections, making his work highly relevant to translational pharmacology and infectious disease research.

Research Focus

Key Achievements

2
H-Index
2
Papers
12
Total Citations
6
Avg Citations/Paper
🏆 Most Cited Paper
In Vitro Pharmacokinetic/Pharmacodynamic Modeling of HIV Latency Reversal by Novel HDAC Inhibitors Using an Automated Platform
6 citations · 2021
📈 Most Prolific Year: 2021 (1 Papers)
🤝 Key Collaborators: 16
🏛 Institutions: Merck & Co., Inc., Rahway, NJ, USA (United States)

Top Papers

  1. 1
  2. 2

Key Collaborators

Contact & Links

Available for collaboration
Content generated · 12 days ago